[Immunoinflammatory factors in unstable angina. Possibility of influence of atorvastatin].
In 101 patients with ischemic heart disease (unstable angina class I and II-III) with hypercholesterolemia at the background of standard therapy (51 patients) and after administration of atorvastatin (50 persons) prescribed from first day of hospitalization in mean dose 10.8 +/- 0.1 mg/day immune status was studied in accordance with 3 stage scheme of examination. In dynamics (before onset of treatment and after 6 months of therapy) a concentrations of a row of cytokines was studied: alpha-factor of tumor necrosis (TNFalpha) and C-reactive protein (CRP). At correlation analysis of parameters of plasma lipid composition and immune profile it has been established that in patients with unstable angina (in the presence of hypercholesterolemia) together with elevation of CRP level substantial signs of dysbalance in immune system are observed. These signs appear as elevation of levels of TNFalpha, interleukin-4, and especially interferon gamma with simultaneous depression of cells of immune defense. In has been demonstrated that atorvastatin not only exerts good hypolipidemic effect, but is capable to diminish immunoinflammatory shifts in patients with acute coronary pathology.
Logacheva
I V
IV
Kazantseva
M O
MO
D000789:Angina, Unstable / Q000097:blood / Q000188:drug therapy / Q000276:immunology*; D000069059:Atorvastatin; D002097:C-Reactive Protein / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D005260:Female; D005500:Follow-Up Studies; D006538:Heptanoic Acids / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D007111:Immunity, Cellular / Q000187:drug effects* / Q000276:immunology; D007249:Inflammation / Q000097:blood / Q000276:immunology*; D015847:Interleukin-4 / Q000097:blood; D008297:Male; D008875:Middle Aged; D011758:Pyrroles / Q000008:administration & dosage / Q000627:therapeutic use*; D013601:T-Lymphocytes / Q000276:immunology; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000097:blood
D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011758:Pyrroles; D014409:Tumor Necrosis Factor-alpha; D015847:Interleukin-4; D002097:C-Reactive Protein; D000069059:Atorvastatin